Michael E Roth, Susan K Parsons, Patricia A Ganz, Lynne I Wagner, Pamela S Hinds, Sarah Alexander, Kristin Bingen, Sharon L Bober, Julienne Brackett, David Cella, N Lynn Henry, Daniel J Indelicato, Rebecca H Johnson, Tamara P Miller, Shoshana M Rosenberg, Kathryn H Schmitz, Gita Thanarajasingam, Bryce B Reeve, John M Salsman
Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes...
October 21, 2022: Journal of the National Cancer Institute